STC's cryosurgical system's expanded uses:
This article was originally published in Clinica
STC Technologies has received 510(k) clearance from the US FDA to market its Histofreezer portable cryosurgical system for treating actinic keratosis and lentigo (liver spots). Acitinic keratosis is often a precursor to skin cancer and if treated early, remains harmless, according to the Lehigh Valley, Pennsylvania-based company. The device consists of a canister of cryogen which is applied to the lesions through an attached foam bud and is also used for the treatment of other skin abnormalities such as common warts and genital lesions.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.